Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Diphosphoinositol polyphosphate phosphohydrolase 3-beta (NUDT11) is an enzyme belonging to the nudix hydrolase family, with specificity for diphosphoinositol polyphosphates. It catalyzes the removal of a beta-phosphate from diphosphate groups in molecules such as PP-InsP5 (diphosphoinositol pentakisphosphate), and can also act on dinucleoside oligophosphates including Ap6A and Ap5A, producing products like ADP, ATP, and p4a. NUDT11 is implicated in signal transduction and may modulate cellular stress responses and apoptosis, as well as play a role in prostate cancer pathogenesis, where its suppression affects cellular proliferation, viability, and colony formation in prostate cell lines. Tissue expression is enriched in the brain, with differential expression compared to its paralog NUDT10. No known drug interactions, biomarkers, or specific therapeutic safety concerns were identified in current literature.
Hydrolysis of beta-phosphate from diphosphoinositol polyphosphates, which may regulate cellular signaling pathways
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Diphosphoinositol polyphosphate phosphohydrolase 3-beta (NUDT11).